Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 746

Results For "ENT"

9386 News Found

Moderna finalizes plan for long-term strategic partnership with Canada
Biotech | May 01, 2022

Moderna finalizes plan for long-term strategic partnership with Canada

Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually


Genome Insight draws US $ 23 million in Series B Funding
Startup | May 01, 2022

Genome Insight draws US $ 23 million in Series B Funding

Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application


India’s pharma exports grow by 103% since 2013-14
News | May 01, 2022

India’s pharma exports grow by 103% since 2013-14

Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions


Once-weekly icodec demonstrates superior reduction in HbA1c vs degludec
Biotech | April 29, 2022

Once-weekly icodec demonstrates superior reduction in HbA1c vs degludec

In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec


Ultomiris approved in the US for adults with generalised myasthenia gravis
Drug Approval | April 29, 2022

Ultomiris approved in the US for adults with generalised myasthenia gravis

Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks


Philips and Prisma Health sign multi-year, long-term strategic partnership
Digitisation | April 29, 2022

Philips and Prisma Health sign multi-year, long-term strategic partnership

South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim


Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Biotech | April 29, 2022

Camzyos is the first and only USFDA-approved cardiac myosin inhibitor

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo


AstraZeneca expands its ‘Young Health Program’ in Delhi
Public Health | April 29, 2022

AstraZeneca expands its ‘Young Health Program’ in Delhi

For over a decade, AstraZeneca and Plan India’s Young Health Program have been generating awareness and identifying sustainable solutions to influence the behaviour of youths against Non-Communicable Diseases


Moderna files for authorization of its Covid-19 vaccine in young children six months to six years
Biotech | April 29, 2022

Moderna files for authorization of its Covid-19 vaccine in young children six months to six years

Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children


Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity
Biotech | April 29, 2022

Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity

Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study